Weekly Tech+Bio Highlights #67: Wrapping Up 2025

First-wave drug builder steps back from the clinic, platform-native developer heads for IPO, a model-discovered drug enters Phase 1, pharma licenses external discovery capacity

Hi! This is BiopharmaTrend’s weekly newsletter, Where Tech Meets Bio, where we explore technologies, breakthroughs, and cutting-edge companies.

As we close out the year, thank you for reading us in 2025. Wishing you a good holiday season and a strong year ahead!

If this newsletter is in your inbox, it’s because you subscribed, or someone thought you might…